This version of the Brighton Collaboration Case Definition of the term “Thrombosis” and “Thromboembolism” was submitted to Vaccine for publication on August 10th, 2022. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) as part of the Safety Platform for Emergency vACcines (SPEAC) project, in the context of active development of vaccines for COVID-19 and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus case definition and defined levels of diagnostic certainty, after an exhaustive review of the literature and expert consultation.
Note: The previously posted version of the Thrombosis and Thromboembolism Brighton case definition had some small errors that have been corrected in this updated version submitted to Vaccine. The main substantive change was in the Preamble, Section 2.1 (Incidence of Thrombosis and thromboembolism): an erroneous statement (that the overall incidence was bimodal with peaks in < 18 year olds and older individuals ) was removed and the sentence amended to note the strong correlation between aging and increased incidence of thrombosis and thromboembolism. A new sentence was added to the section describing the relevant pediatric epidemiology as follows: A trend for increased VTE diagnosis was reported in about 40 children’s hospitals in the US There were also some corrections to the section on first line investigation modalities involving Table 2 ( “First line and alternate techniques for diagnosing thrombosis and thromboembolism, by location”) and the text section on diagnosis that followed Table 2. The changes were made to ensure alignment of the table with the text but there were no substantive changes in terms of what was recommended.
This post will be updated once the Case Definition has been published.